Illuminating HDL--is it still a viable therapeutic target?
Rader
Daniel J
DJ
D000924:Anticholesteremic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016632:Apolipoprotein A-I / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000188:drug therapy / Q000401:mortality*; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors*; D008076:Cholesterol, HDL / Q000097:blood*; D006801:Humans; D011804:Quinolines / Q000009:adverse effects*; D015854:Up-Regulation
D000924:Anticholesteremic Agents; D016632:Apolipoprotein A-I; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL; D011804:Quinolines; C483909:torcetrapib